The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of perioperative complications on ctDNA-based MRD detection and prognosis: Insights from the GALAXY study.
 
Eiji Oki
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Guardant Health
 
Shota Sato
No Relationships to Disclose
 
Koji Ando
No Relationships to Disclose
 
Yoshiaki Nakamura
Consulting or Advisory Role - DAIICHI SANKYO Co., Ltd.; Exact Sciences; Gilead Sciences; Guardant Health Pte Ltd; Natera,Inc.; Premo Partners, Inc.; Roche Ltd./; Seagen,Inc.; Takeda
Speakers' Bureau - Becton Dickinson; CareNet,Inc.; Chugai Pharma; DAIICHI SANKYO Co., Ltd.; Eisai; Guardant Health Japan Corp.; Guardant Health Pte Ltd; Hisamitsu Pharmaceutical; Merck; Miyarisan pharmaceutical; MSD K.K; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - Chugai Pharma (Inst); DAIICHI SANKYO Co., Ltd. (Inst); Genomedia (Inst); Guardant Health (Inst); Guardant Health AMEA, Inc. (Inst); Roche (Inst); Seagen,Inc. (Inst); Tempus (Inst)
 
Jun Watanabe
Honoraria - Covidien; Johnson & Johnson/MedTech; Lilly; Takeda; TERUMO
Research Funding - Covidien (Inst); Stryker (Inst); TERUMO (Inst)
 
Naoya Akazawa
No Relationships to Disclose
 
Keiji Hirata
No Relationships to Disclose
 
Kozo Kataoka
Honoraria - Guardant Health; Lilly; Merck; Takeda
Research Funding - Nakatani Foundation; Sysmex
 
Mitsuru Yokota
No Relationships to Disclose
 
Kentaro Kato
No Relationships to Disclose
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly; Takeda
 
Kun-Huei Yeh
Honoraria - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Merck; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Daiichi Sankyo/Astra Zeneca; Daiichi Sankyo/Astra Zeneca; DSI/AZ; MSD; MSD; Novartis; Pfizer; Pierre Fabre; Takeda
Travel, Accommodations, Expenses - Ono Pharmaceutical; Pfizer; Takeda
 
Arkarachai Fungtammasan
Employment - Natera
Stock and Other Ownership Interests - Natera
Travel, Accommodations, Expenses - Natera
 
Adham Jurdi
Employment - Natera
Stock and Other Ownership Interests - Agenus; Iovance Biotherapeutics; natera; Verastem
 
Minetta Liu
Employment - Natera
Stock and Other Ownership Interests - Natera
 
Daisuke Kotani
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Guardant Health; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sysmex; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - MSD K.K; Seagen; Takeda
Research Funding - CMIC (Inst); CMIC (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); SERVIER (Inst); Syneos Health (Inst)
 
Hideaki Bando
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical
 
Ichiro Takemasa
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Asahi Kasei; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Takayuki Yoshino
Honoraria - Chugai Pharma; Merck; MSD K.K.; Takeda
Consulting or Advisory Role - Sumitomo Corp.
Research Funding - Amgen (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); Eisai (Inst); FALCO biosystems Ltd. (Inst); Medical & Biological Laboratories Co., Ltd. (Inst); Merus (Inst); Molecular Health (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)